CA-CONVIVA
4.11.2021 17:02:13 CET | Business Wire | Press release
Despite predictions of a ”pandemic peak,” streaming adoption continues to gain ground in almost every single region quarter after quarter, according to the Q3 2021 State of Streaming report from Conviva, the continuous measurement platform for streaming media. Streaming viewing time grew 21% worldwide in Q3 2021 as compared to the same quarter in 2020, led by Africa, Oceania and South America while North America, an established streaming market, held steady with the most modest growth of any region, up just 2%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005139/en/
“Streaming viewing has grown 266% over the past three years, completely transforming the entertainment, publishing and advertising industries,” said Keith Zubchevich, CEO, Conviva. “Topics like quality of experience, advertising measurement and social engagement are now top of mind and the publishers that effectively leverage opportunities to improve in these areas will not only lead the industry in subscribers and viewer satisfaction, but also revenue.”
The report also found streaming publishers investing heavily in video content on social media platforms in Q3 2021 – especially YouTube – in order to test new content and promote their catalog with viewers. In fact, streaming platforms increased their content output on YouTube by 97%, which resulted in an 8.4% increase in views and a 24% increase in engagement. Audiences for streaming platform accounts grew by 66% on YouTube in Q3 2021 as compared to Q3 2020.
Buffering Nearly Eliminated; Higher Quality = Higher Engagement
Q3 2021 marks the first quarter all regions experienced sub-1% buffering, with buffering seeing the largest improvements in more nascent regions like Africa, down 78% year over year. North America had the most modest gains over last year, with a 29% reduction in buffering, which was enough to maintain its position as the region with the least buffering at just 0.19%. Year over year, picture quality also made gains with bitrate improving in every region.
Higher quality delivered higher consumer engagement across the board. When buffering rates were less than 0.4%, viewers engaged for an average of 28.44 minutes in Q3, with that steadily declining with each incremental increase in buffering. Similarly, higher picture quality correlated with higher engagement as viewers averaged more than 20 minutes at bitrates above 3.5 Mbps in Q3 with engagement declining as bitrates dropped.
Big screen domination persisted
Despite seeing a slight decrease in share over Q3 of last year, big screens – which includes connected TV devices, smart TVs and gaming consoles – still accounted for almost three quarters (73%) of viewing time worldwide. Roku, Amazon Fire TV and Samsung TV made up the bulk of big screen viewing time globally with Roku again coming out on top with 31.1% share. Amazon Fire TV fell from 20% in Q3 2020 to 16.8% in Q3 2021, while Samsung gained nearly 3 percentage points over Q3 of last year going from 9.4% to 12.2% share of global viewing time. LG TV, Android TV, Apple TV and Chromecast also gained share over last year.
In every part of the world except Asia, big screens were the majority of viewership, particularly in North America with 82%. Mobile phones, desktops and tablets barely registered in North America at 8%, 6% and 4%, respectively.
Advertising continues advances in streaming
Streaming advertising made significant gains in Q3 2021. Ad attempts and ad impressions were up over 30% in Q3 2021, as compared to Q2 2021. Just 15% of ads in Q3 2021 were not delivered as intended, for a 23% decrease in missed ad opportunities quarter over quarter. Ad duration decreased by 3% from last quarter to 26 seconds, satisfying consumer requests for shorter ad breaks. Advertising quality was a mixed bag in Q3 2021, as ad buffering worsened by 22% and picture quality decreased 1% from last quarter.
Download the full report here .
Methodology
Conviva’s data is primarily collected using proprietary sensor technology with a global footprint of more than 500 million unique viewers watching 180 billion streams per year across nearly 4 billion applications streaming on devices. Embedded directly within streaming video applications, the sensor measures across content and ads to analyze nearly three trillion real-time transactions per day for its customers. In the State of Streaming report, the year-over-year data from Q3 2021 as compared to Q3 2020 was normalized based on Conviva’s customer base. The social media data consists of data from over 2800 accounts, over 21 million posts, and over 18 billion engagements across Facebook, Instagram, Twitter, and YouTube in Q3 2021.
About Conviva
Conviva is the census, continuous measurement and engagement platform for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005139/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom